Quantitative bioactivity prediction and pharmacophore identification for benzotriazine derivatives using the electron conformational-genetic algorithm in QSAR

SAR and QSAR in Environmental Research

Volumn 22, Issue 3-4, 2011, Pages 217-238

  Sahin K ^a   Saripinar, E ^b   Yanmaz, E ^b   Gecen N ^b  

^a BITLIS EREN UNIVERSITY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

Benzotriazines; Drug design; Genetic algorithm; Molecular modelling; Pharmacophore

Indexed keywords

COMPUTATIONAL CHEMISTRY; CONFORMATIONS; ELECTRONIC STRUCTURE; ELECTRONS; FORECASTING; MOLECULAR GRAPHICS; PHARMACODYNAMICS;

BENZOTRIAZINE; BIOACTIVITY PREDICTION; DRUG DESIGN; ELECTRONIC.STRUCTURE; GEOMETRY STRUCTURE; HYBRID APPROACH; MATRIX; PHARMACOPHORES; QUANTITATIVE PREDICTION; SUBMATRIX;

GENETIC ALGORITHMS;

EID: 79957827303     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2010.548341     Document Type: Article

References (51)

1. C. Gueto, J.L. Ruiz, J.E. Torres, J. Mendez, and R. Vivas-Reyes, Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA, Bioorg. Med. Chem. 16 (2008), pp. 2439-2447.
2. G. Noronha, K. Barrett, J. Cao, E. Dneprovskaia, R. Fine, X. Gong, C. Gritzen, J. Hood, X. Kang, B. Klebansky, G. Li, W. Liao, D. Lohse, C.C. Mak, A. McPherson, M.S. Palanki, V.P. Pathak, J. Renick, R. Soll, U. Splittgerber, W. Wrasidlo, B. Zeng, N. Zhao, and Y. Zhou, Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors, Bioorg. Med. Chem. Lett. 16 (2006), pp. 5546-5550.
3. J.L. Lv, R. Wang, D. Liu, G. Guo, Y.K. Jing, and L.X. Zhao, Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines, Molecules 13 (2008), pp. 1427-1440.
4. C. Tintori, M. Magnani, S. Schenone, and M. Botta, Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors, Eur. J. Med. Chem. 44 (2009), pp. 990-1000.
5. C.A. Taft, V.B. Silva, and C.H.T.P. Silva, Current topics in computer-aided drug design, J. Pharmacol. Sci. 97 (2008), pp. 1089-1098.
6. A. Itai, N. Tomoika, and K. Kato, Rational approaches to computer drug design based on drugreceptor interactions, in QSAR and Drug Design: New Developments and Applications, 23rd ed., Toshio Fujita, ed., Elsevier Science Publishing, Amsterdam, Netherlands, 1995.
7. M. Deshpande, M. Kuramochi, N. Wale, and G. Karypis, Frequent substructure-based approaches for classifying chemical compounds, IEEE Trans. Knowl. Data Eng. 17 (2005), pp. 1036-1050.
8. J.P.A. Martins, E.G. Barbosa, K.F.M. Pasqualoto, and M.M.C. Ferreira, LQTA-QSAR: A New 4D-QSAR Methodology, J. Chem. Inf. Model. 49 (2009), pp. 1428-1436.
9. A.J. Hopfinger, S. Wang, S. Tokarski, B. Jin, M. Albuquerque, J. Madhav, and C. Duraiswami, Construction of 3D-QSAR models using the 4D-QSAR analysis formalism, J. Am. Chem. Soc. 119 (1997), pp. 10509-10524.
10. P. Venkatarangan and A.J. Hopfinger, Prediction of ligand-receptor binding free energy by 4D-QSAR analysis: Application to a set of glucose analogue inhibitors of glycogen phosphorylase, Chem. Inf. Comput. Sci. 39 (1999), pp. 1141-1150.
11. M.D. Krasowski, X. Hong, A.J. Hopfinger, and N.L. Harrison, 4D-QSAR analysis of a set of propofol analogues: Mapping binding sites for an anesthetic phenol on the GABAA receptor, J. Med. Chem. 45 (2002), pp. 3210-3221.
12. X. Hong and A.J. Hopfinger, 3D-pharmacophores of flavonoid binding at the benzodiazepine GABAA receptor site using 4D-QSAR analysis, J. Chem. Inf. Comput. Sci. 43 (2003), pp. 324-336.
13. E. Rosines, I.B. Bersuker, and J.E. Boggs, Pharmacophore identification and bioactivity prediction for Group I metabotropic glutamate receptor agonists by the electron-conformational QSAR method, Quant. Struct.-Act. Relat. 20 (2001), pp. 327-333.
14. Al H. Makkouk, I.B. Bersuker, and J.E. Boggs, Quantitative drug activity prediction for inhibitors of human breast carcinoma, Int. J. Pharm. Med. 18 (2004), pp. 81-89.
15. A.V. Marenich, P.H. Yong, I.B. Bersuker, and J.E. Boggs, Quantitative antidiabetic activity prediction for the class of guanidino- and aminoguanidinopropionic acid analogs based on electronconformational studies, J. Chem. Inf. Model. 48 (2008), pp. 556-568.
16. I.B. Bersuker, QSAR without arbitrary descriptors: The electron-conformational method, J. Comp. Aid. Mol. Des. 22 (2008), pp. 423-430.
17. M. Karelson, Molecular Descriptors in QSAR/QSPR, Wiley-Interscience, New York, 2000.
18. L. Bernazzani, C. Duce, A. Micheli, V. Mollica, A. Sperduti, A. Starita, and M.R. Tine, Predicting physical-chemical properties of compounds from molecular structures by recursive neural networks, J. Chem. Inf. Model. 46 (2006), pp. 2030-2042.
19. I. Guyon and A. Elisseeff, An introduction to variable and feature selection, J. Machine Learn. Res. 3 (2003), pp. 1157-1182.
20. J.M. Sutter, S.L. Dixon, and P.C. Jurs, Automated descriptor selection for quantitative structure-activity relationships using generalized simulated annealing, J. Chem. Inf. Comput. Sci. 35 (1995), pp. 77-84.
21. O. Nicolotti, V.J. Gillet, P.J. Fleming, and D.V.S. Gren, Multiobjective optimization in quantitative structure-activity relationships: Deriving accurate and interpretable QSARs, J. Med. Chem. 45 (2002), pp. 5069-5080.
22. L. Terfloth and J. Gasteiger, Neural networks and genetic algorithms in drug design, Drug Discovery Today. 6 (2001), pp. 102-108.
23. H. Kubinyi, Variable selection in QSAR studies: Part I. An evolutionary algorithm, Quant. Struct. Act. Relat. 13 (1994), pp. 285-294.
24. H. Kubinyi, Variable selection in QSAR studies: Part II. Highly efficient combination of systematic search and evolution, Quant. Struct. Act. Relat. 13 (1994), pp. 393-401.
25. C.L. Waller and M.P. Bradley, Development and validation of a novel variable selection technique with application to multidimensional quantitative structure-activity relationship studies, J. Chem. Inf. Comput. Sci. 39 (1999), pp. 345-355.
26. G. Guerrini, G. Ciciani, G. Cambi, F. Bruni, S. Selleri, C. Guarino, F. Melani, M. Montali, C. Martini, C. Ghelardini, M. Norcini, and A. Costanzo, Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives: Identification of a bifunctional hydrogen bond area related to the inverse agonism, J. Med. Chem. 52 (2009), pp. 4668-4682.
27. E. Saripinar, N. Geçen, K. Sahin, and E. Yanmaz, Pharmacophore identification and bioactivity prediction for triaminotriazine derivatives by electron conformational-genetic algorithm QSAR method, Eur. J. Med. Chem. 45 (2010), pp. 4157-4168.
28. G. Noronha, K. Barrett, A. Boccia, T. Brodhag, J. Cao, C. Chow, E. Dneprovskaia, J. Doukas, R. Fine, X. Gong, C. Gritzen, H. Gu, E. Hanna, J. Hood, S. Hu, X. Kang, J. Key, B. Klebansky, A. Kousba, G. Li, D. Lohse, C.C. Mak, A. McPherson, M.S.S. Palanki, V.P. Pathak, J. Renick, F. Shi, R. Soll, U. Splittgerber, S. Stoughton, S. Tang, S. Yee, B. Zeng, N. Zhao, and H. Zhu, Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-amine-a potent, orally active Src kinase inhibitor with antitumor activity in preclinical assays, Bioorg. Med. Chem. Lett. 17 (2007), pp. 602-608.
29. SPARTAN, Version 06; Wavefunction, Irvine, CA, USA, 2006.
30. M.J. Vainio and M.S. Johnson, McQSAR: A multiconformational quantitative structure-activity relationship engine driven by genetic algorithms, J. Chem. Inf. Model. 45 (2005), pp. 1953-1961.
31. W.J. Hehre, A Guide to Molecular Mechanics and Quantum Chemical Calculations, Wavefunction, Irvine, CA, USA, 2003.
32. I.B. Bersuker, Pharmacophore identification and quantitative bioactivity prediction using the electron-conformational method, Curr. Pharm. Des. 9 (2003), pp. 1575-1606.
33. V. Librando and A. Alparone, The role of electronic properties to the mutagenic activity of 1,6- and 3,6-dinitrobenzo[a]pyrene isomers, J. Hazard. Mater. 161 (2009), pp. 1338-1346.
34. I.B. Bersuker, S. Bahceci, and J.E. Boggs, Improved electron-conformational method of pharmacophore identification and bioactivity prediction: Application to angiotensin converting enzyme inhibitors, J. Chem. Inf. Comput. Sci. 40 (2000), pp. 1363-1376.
35. A.S. Dimoglu, P.F. Vlad, N.M. Shvets, M.N. Coltsa, Y. Guzel, M. Saracoglu, E. Saripinar, and S. Patat, Electronic-topological investigations of the relationships between chemical structure and ambergris odor, New J. Chem. 19 (1995), pp. 1217-1226.
36. I.B. Bersuker, S. Bahceci, J.E. Boggs, and R.S. Pearlman, An electron-conformational method of identification of pharmacophore and anti-pharmacophore shielding: Application to rice blast activity, J. Comput.-Aided Mol. Des. 13 (1999), pp. 419-434.
37. A. Altun, K. Golcuk, M. Kumru, and A.F. Jalbout, Electron-conformational study for the structure-hallucinogenic activity relationships of phenylalkylamines, Bioorg. Med. Chem. 11 (2003), pp. 3861-3868.
38. O.F. Guner, Pharmacophore Perception, Development, and Use in Drug Design, International University Line, La Jolla, CA, USA, 2000.
39. J. Weitz, M. Koch, J. Debus, T. Hohler, P.R. Galle, and M.W. Buchler, Colorectal cancer, Lancet 365 (2005), pp. 153-165.
40. MATLAB, version 7.0, MathWorks, Natick, MA, USA.
41. P. Gramatica, P. Pilutti, and E. Papa, Validated QSAR prediction of OH tropospheric degradability: Splitting into training-test set and consensus modeling, J. Chem. Inf. Comput. Sci. 44 (2004), pp. 1794-1802.
42. F. Kandemirli, N. Tokay, N.M. Shvets, and A.S. Dimoglu, Investigation of structure-activity relationship on 17-spirolactone derivatives: The electronic-topological approach, Il Farmaco. 57 (2002), pp. 601-607.
43. Y. Guzel, E. Saripinar, and I. Yildirim, Electron-topological (ET) investigation of structure- antagonist activity of a series of dibenzo[a,d]cycloalkenimines, J. Mol. Struct.: Theochem. 418 (1997), pp. 83-91.
44. E. Saripinar, Y. Guzel, S. Patat, I. Yildirim, Y. Akcamur, and A.S. Dimoglu, Electron- topological investigation of the relationship structure-antitubercular activity of thiosemicarbasone derivatives, Arzneim. Forsch. 46 (1996), pp. 824-828.
45. F. Kandemirli, N. Shvets, V. Kovalishyn, and A.S. Dimoglu, Combined electronic-topological and neural networks study of some hydroxysemicarbazides as potential antitumor agents, J. Molec. Graphics Modelling 25 (2006), pp. 30-36.
46. http://www.borland.com/delphi
47. M.A. Riel, D.E. Kyle, A.K. Bhattacharjee, and W.K. Milhous, Efficacy of proton pump inhibitor drugs against plasmodium falciparum in vitro and their probable pharmacophores, Antimicrob. Agents Chemother. 46 (2002), pp. 2627-2632.
48. F. Fan, J. Cheng, Z. Li, X. Xu, and X. Qian, Novel dimer based descriptors with solvational computation for qsar study of oxadiazoylbenzoyl-ureas as novel insect-growth regulators, J. Comput. Chem. 31 (2009), pp. 586-591.
49. 2, J. Molec. Graphics Model. 20 (2002), pp. 269-276.
50. D. Livingstone, Data Analysis for Chemists, Oxford University Press, Oxford, 1995.
51. S. Wold, Cross-validatory estimation of the number of components in factor and principal components models, Technometrics 20 (1978), pp. 397-405.